nach oben

European Journal of Clinical Microbiology & Infectious Diseases

Erschienen in:

01.05.2011 | Article

Serratia infections in a general hospital: characteristics and outcomes

verfasst von: G. Samonis, E. K. Vouloumanou, M. Christofaki, D. Dimopoulou, S. Maraki, E. Triantafyllou, D. P. Kofteridis, M. E. Falagas

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 5/2011

Einloggen, um Zugang zu erhalten

Abstract

We aimed to present our experience regarding infections caused by Serratia spp. in a region with relatively high antimicrobial resistance rates. We retrospectively reviewed the databases of the microbiological laboratory of the University Hospital of Heraklion, Crete (2/2004–12/2009). A total of 77 patients [67.5% men, mean age ± standard deviation (SD) = 56.9 ± 24.5 years) were identified; 37.7% were outpatients. Sixty-five (84.4%) of the 77 included patients had a Serratia marcescens isolate; the remaining 12 patients had a non-marcescens Serratia spp. The most frequently observed infections were respiratory tract infection (32.5%) and keratitis/endophthalmitis (20.8%). Seventy-three (94.9%) patients were cured. Four deaths were observed; three of them were considered as attributed to the Serratia infection. No difference was found regarding the characteristics and outcomes between patients with Serratia marcescens and non-marcescens infections. In addition, antipseudomonal penicillins and their combinations with beta-lactamase inhibitors, as well as carbapenemes, and fluoroquinolones exhibited high antimicrobial activity against both the tested Serratia marcescens and non-marcescens isolates. Our study adds useful information regarding the characteristics and outcomes of patients with Serratia infection, as well as the susceptibilities of the respective Serratia marcescens and non-marcescens isolates, in a region with relatively high levels of antimicrobial resistance.

Chemaly RF, Rathod DB, Raad II (2009) A tertiary care cancer center experience of the 2007 outbreak of Serratia marcescens bloodstream infection due to prefilled syringes. Infect Control Hosp Epidemiol 30:1237–1238PubMedCrossRef

Kim JH, Choi WH, Yun SW, Chae SA, Yoo BH (2010) An outbreak of Serratia marcescens Sepsis in a pediatric ward. Clin Pediatr (Phila) 49(10):1000–1002

Arslan U, Erayman I, Kirdar S et al (2010) Serratia marcescens sepsis outbreak in a neonatal intensive care unit. Pediatr Int 52:208–212PubMedCrossRef

Dessi A, Puddu M, Testa M, Marcialis MA, Pintus MC, Fanos V (2009) Serratia marcescens infections and outbreaks in neonatal intensive care units. J Chemother 21:493–499PubMed

Voelz A, Muller A, Gillen J et al (2010) Outbreaks of Serratia marcescens in neonatal and pediatric intensive care units: clinical aspects, risk factors and management. Int J Hyg Environ Health 213:79–87PubMedCrossRef

Pinna A, Usai D, Sechi LA, Carta A, Zanetti S (2009) Detection of virulence factors in Serratia strains isolated from contact lens-associated corneal ulcers. Acta Ophthalmol [Epub ahead of print]

Szczotka-Flynn LB, Imamura Y, Chandra J et al (2009) Increased resistance of contact lens-related bacterial biofilms to antimicrobial activity of soft contact lens care solutions. Cornea 28:918–926PubMedCrossRef

Laupland KB, Parkins MD, Gregson DB, Church DL, Ross T, Pitout JD (2008) Population-based laboratory surveillance for Serratia species isolates in a large Canadian health region. Eur J Clin Microbiol Infect Dis 27:89–95PubMedCrossRef

Dalamaga M, Pantelaki M, Karmaniolas K, Matekovits A, Daskalopoulou K (2008) Cutaneous abscess and bacteremia due to Serratia ficaria. J Eur Acad Dermatol Venereol 22:1388–1389PubMedCrossRef

10.

Dubouix A, Roques C, Segonds C et al (2005) Epidemiological investigation of a Serratia liquefaciens outbreak in a neurosurgery department. J Hosp Infect 60:8–13PubMedCrossRef

11.

Grohskopf LA, Roth VR, Feikin DR et al (2001) Serratia liquefaciens bloodstream infections from contamination of epoetin alfa at a hemodialysis center. N Engl J Med 344:1491–1497PubMedCrossRef

12.

Mostafa E, Mohammed F, Abdelhamid Z, Tahar B, Sakina E, Belkacem C (2008) Septic pseudarthrosis caused by Serratia plymuthica. Joint Bone Spine 75:506–507PubMedCrossRef

13.

Crivaro V, Bagattini M, Salza MF et al (2007) Risk factors for extended-spectrum beta-lactamase-producing Serratia marcescens and Klebsiella pneumoniae acquisition in a neonatal intensive care unit. J Hosp Infect 67:135–141PubMedCrossRef

14.

Mlynarczyk A, Szymanek K, Sawicka-Grzelak A et al (2009) CTX-M and TEM as predominant types of extended spectrum beta-lactamases among Serratia marcescens isolated from solid organ recipients. Transplant Proc 41:3253–3255PubMedCrossRef

15.

Rizvi M, Fatima N, Shukla I, Malik A (2010) Epidemiology of extended spectrum beta-lactamases in Serratia and Citrobacter species in North India. Indian J Pathol Microbiol 53:193–194PubMedCrossRef

16.

Falagas ME, Maraki S, Karageorgopoulos DE, Kastoris AC, Kapaskelis A, Samonis G (2010) Antimicrobial susceptibility of Gram-positive non-urinary isolates to fosfomycin. Int J Antimicrob Agents 35:497–499PubMedCrossRef

17.

Falagas ME, Maraki S, Karageorgopoulos DE, Kastoris AC, Mavromanolakis E, Samonis G (2010) Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin. Int J Antimicrob Agents 35:240–243PubMedCrossRef

18.

Maraki S, Samonis G, Rafailidis PI, Vouloumanou EK, Mavromanolakis E, Falagas ME (2009) Susceptibility of urinary tract bacteria to fosfomycin. Antimicrob Agents Chemother 53:4508–4510PubMedCrossRef

19.

Samonis G, Maraki S, Rafailidis PI, Kapaskelis A, Kastoris AC, Falagas ME (2010) Antimicrobial susceptibility of Gram-negative nonurinary bacteria to fosfomycin and other antimicrobials. Future Microbiol 5:961–970PubMedCrossRef

20.

Samonis G, Matthaiou DK, Kofteridis D, Maraki S, Falagas ME (2010) In vitro susceptibility to various antibiotics of colistin-resistant gram-negative bacterial isolates in a general tertiary hospital in Crete, Greece. Clin Infect Dis 50:1689–1691PubMedCrossRef

21.

Farmer JJ III, Boatwright KD, Janda JM (2007) Enterobacteriaceae: Introduction and identification. In: Murray P, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA (eds) Manual of clinical microbiology, vol 1, 9th edn. American Society for Microbiology, Washington, pp 649–669

22.

Clinical and Laboratory Standards Institute (2009) Performance standards for antimicrobial susceptibility testing; Nineteenth informational supplement. CLSI Document M100-S19, Wayne, PA, USA

23.

Dean A, Sullivan K, Soe M (2008) OpenEpi: open source epidemiologic statistics for public health, version 2.2.1. Updated 2008/04/06. Available from: www.OpenEpi.com. Cited 18 September 2008

24.

Engel HJ, Collignon PJ, Whiting PT, Kennedy KJ (2009) Serratia sp. bacteremia in Canberra, Australia: a population-based study over 10 years. Eur J Clin Microbiol Infect Dis 28:821–824PubMedCrossRef

25.

Rice SA, Koh KS, Queck SY, Labbate M, Lam KW, Kjelleberg S (2005) Biofilm formation and sloughing in Serratia marcescens are controlled by quorum sensing and nutrient cues. J Bacteriol 187:3477–3485PubMedCrossRef

26.

Van Houdt R, Givskov M, Michiels CW (2007) Quorum sensing in Serratia. FEMS Microbiol Rev 31:407–424PubMedCrossRef

27.

Molina-Cabrillana J, Rodriguez-Bermejo JC, del Rosario-Quintana C, Bolanos-Rivero M (2007) Rapid detection of an outbreak of bronchoscopy-associated colonization by Serratia marcescens. Enferm Infecc Microbiol Clín 25:222–224PubMedCrossRef

28.

Jones GL, Muller CT, O'Reilly M, Stickler DJ (2006) Effect of triclosan on the development of bacterial biofilms by urinary tract pathogens on urinary catheters. J Antimicrob Chemother 57:266–272PubMedCrossRef

29.

Horcajada JP, Martinez JA, Alcon A et al (2006) Acquisition of multidrug-resistant Serratia marcescens by critically ill patients who consumed tap water during receipt of oral medication. Infect Control Hosp Epidemiol 27:774–777PubMedCrossRef

30.

de Vries JJ, Baas WH, van der Ploeg K, Heesink A, Degener JE, Arends JP (2006) Outbreak of Serratia marcescens colonization and infection traced to a healthcare worker with long-term carriage on the hands. Infect Control Hosp Epidemiol 27:1153–1158PubMedCrossRef

31.

Casolari C, Pecorari M, Fabio G et al (2005) A simultaneous outbreak of Serratia marcescens and Klebsiella pneumoniae in a neonatal intensive care unit. J Hosp Infect 61:312–320PubMedCrossRef

32.

Johnson JS, Croall J, Power JS, Armstrong GR (1998) Fatal Serratia marcescens meningitis and myocarditis in a patient with an indwelling urinary catheter. J Clin Pathol 51:789–790PubMedCrossRef

33.

Kim BN, Choi SI, Ryoo NH (2006) Three-year follow-up of an outbreak of Serratia marcescens bacteriuria in a neurosurgical intensive care unit. J Korean Med Sci 21:973–978PubMedCrossRef

34.

Yu WL, Lin CW, Wang DY (1998) Serratia marcescens bacteremia: clinical features and antimicrobial susceptibilities of the isolates. J Microbiol Immunol Infect 31:171–179PubMed

35.

Parment PA (1997) The role of Serratia marcescens in soft contact lens associated ocular infections. A review. Acta Ophthalmol Scand 75:67–71PubMedCrossRef

36.

Latorre G (2008) Endogenous Serratia marcescens endophthalmitis in a preterm infant. Indian J Pediatr 75:410PubMed

37.

Mah-Sadorra JH, Najjar DM, Rapuano CJ, Laibson PR, Cohen EJ (2005) Serratia corneal ulcers: a retrospective clinical study. Cornea 24:793–800PubMedCrossRef

38.

Chuang TY, Chuang CP, Cheng HH, Hsueh PR (2007) Aortic valve infective endocarditis caused by Serratia liquefaciens. J Infect 54:e161–e163PubMedCrossRef

39.

Sekhsokh Y, Arsalane L, El Ouenass M, Doublali T, Bajjou T, Lahlou Amine I (2007) Serratia rubidaea bacteremia. Méd Mal Infect 37:287–289PubMedCrossRef

40.

Okada T, Yokota E, Matsumoto I (2002) Community acquired sepsis by Serratia rubidaea. Kansenshogaku Zasshi 76:109–112PubMed

41.

Anahory T, Darbas H, Ongaro O, Jean-Pierre H, Mion P (1998) Serratia ficaria: a misidentified or unidentified rare cause of human infections in fig tree culture zones. J Clin Microbiol 36:3266–3272PubMed

42.

Liu J-W, Hsu Y-M, Huang Y-F (2004) Independent prognostic factors for fatality in patients with urinary tract infection caused by Serratia marcescens. Infect Control Hosp Epidemiol 25:80–82PubMedCrossRef

43.

Cheng K-C, Chuang Y-C, Wu L-T, Huang G-C, Yu W-L (2006) Clinical experiences of the infections caused by extended-spectrum beta-lactamase-producing Serratia marcescens at a medical center in Taiwan. Jpn J Infect Dis 59:147–152PubMed

44.

Park YJ, Park SY, Oh EJ et al (2005) Occurrence of extended-spectrum beta-lactamases among chromosomal AmpC-producing Enterobacter cloacae, Citrobacter freundii, and Serratia marcescens in Korea and investigation of screening criteria. Diagn Microbiol Infect Dis 51:265–269PubMedCrossRef

45.

Rizvi M, Fatima N, Rashid M et al (2009) Extended spectrum AmpC and metallo-beta-lactamases in Serratia and Citrobacter spp. in a disc approximation assay. J Infect Dev Ctries 3:285–294PubMed

46.

Kumamoto Y, Tsukamoto T, Matsukawa M et al (2005) Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (2003). I. Susceptibility distribution. Jpn J Antibiot 58:518–543PubMed

47.

Tsou MF, Yu WL, Hung SW et al (2004) Detection of cefotaxime-resistant CTX-M-3 in clinical isolates of Serratia marcescens. Folia Microbiol (Praha) 49:452–456CrossRef

48.

Zhao WH, Hu ZQ, Chen G, Matsushita K, Fukuchi K, Shimamura T (2007) Characterization of imipenem-resistant Serratia marcescens producing IMP-type and TEM-type beta-lactamases encoded on a single plasmid. Microbiol Res 162:46–52PubMedCrossRef

49.

Sheng WH, Chen YC, Wang JT, Chang SC, Luh KT, Hsieh WC (2002) Emerging fluoroquinolone-resistance for common clinically important gram-negative bacteria in Taiwan. Diagn Microbiol Infect Dis 43:141–147PubMedCrossRef

50.

Acar JF, O'Brien TF, Goldstein FW, Jones RN (1993) The epidemiology of bacterial resistance to quinolones. Drugs 45(Suppl 3):24–28PubMedCrossRef

51.

Velasco C, Rodriguez-Martinez JM, Briales A, Diaz de Alba P, Calvo J, Pascual A (2010) Smaqnr, a new chromosome-encoded quinolone resistance determinant in Serratia marcescens. J Antimicrob Chemother 65:239–242PubMedCrossRef

52.

Falagas ME, Karageorgopoulos DE (2009) Extended-spectrum beta-lactamase-producing organisms. J Hosp Infect 73:345–354PubMedCrossRef

Titel: Serratia infections in a general hospital: characteristics and outcomes
verfasst von: G. Samonis
E. K. Vouloumanou
M. Christofaki
D. Dimopoulou
S. Maraki
E. Triantafyllou
D. P. Kofteridis
M. E. Falagas
Publikationsdatum: 01.05.2011
Verlag: Springer-Verlag
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 5/2011
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI: https://doi.org/10.1007/s10096-010-1135-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2011

Significant pathogens in peritonsillar abscesses

Vancomycin MIC creep in MRSA blood culture isolates from Germany: a regional problem?

Identification of gentian violet concentration that does not stain oral mucosa, possesses anti-candidal activity and is well tolerated

Change in hepatitis C virus clades: A cross-sectional study of chronic HCV patients in Pakistan from 2000–2010

Aminoglycoside-resistant staphylococci in Greece: prevalence and resistance mechanisms